Microbicides: latest news

Microbicides resources

  • Microbicides

    Microbicides are any substances which protect people against infection by microbes, such as viruses or bacteria, on contact with those microbes....

    From: Preventing HIV

    Information level Level 4
  • Microbicides

    A microbicide is a topical agent that, when applied to a mucosal surface, serves as a barrier to infection. Microbicides can come in the form of...

    From: HIV transmission & testing

    Information level Level 4

Microbicides features

Microbicides news from aidsmap

More news

Microbicides news selected from other sources

  • IPM's dapivirine ring may offer significant HIV protection when used consistently

    New data analyses announced at the AIDS 2016 conference today provide additional evidence suggesting that the monthly dapivirine vaginal ring developed by the nonprofit International Partnership for Microbicides (IPM) provides significant protection against HIV infection in women when used consistently. The new data were released as two open-label studies of the ring begin and as IPM pursues regulatory approvals for the product for its use in developing countries.

    18 July 2016 | International Partnership for Microbicides
  • Treatment Action Group: Pipeline Report 2016

    Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.

    15 July 2016 | Treatment Action Group
  • Five Exciting HIV Prevention Studies We’re Paying Attention To

    What’s on the horizon of HIV prevention? Here are five clinical trials to pay attention to, if you’re interested in what the next big breakthrough in the HIV prevention field may be.

    30 June 2016 | BETA blog
  • Can a gel to prevent HIV be applied as a lube?

    Rectal microbicide gels, applied either daily or before and after sex, are currently being investigated as an option for HIV pre-exposure prophylaxis (PrEP). Given that many people who have anal lready use lube, one hope is for an HIV-prevention product that people could essentially use in place of a lube. But can gels provide enough coverage across rectal tissue if people don’t use an applicator?

    18 March 2016 | BETA blog
  • NIAID to Fund Further Study of Dapivirine Vaginal Ring for HIV Prevention

    The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announced today that it would move forward with an open-label extension study of an HIV prevention tool for women: a silicone ring that continuously releases the experimental antiretroviral drug dapivirine in the vagina. The new study builds on recently announced findings from the ASPIRE trial which found that the dapivirine ring safely provided a modest level of protection against HIV infection in sub-Saharan African women.

    14 March 2016 | National Institute of Allergy and Infectious Diseases
  • Vaginal ring for HIV prevention: a few details would have elevated good coverage to great

    Analysis of BuzzFeed's coverage of vaginal ring studies.

    01 March 2016 | Health News Review
  • Why a new vaginal ring could be a game-changer in HIV prevention

    This is the first time two phase-three clinical trials have confirmed statistically significant efficacy for a microbicide to prevent HIV. The dapivirine ring was designed to offer potentially long-acting protection against HIV through slow, continuous delivery of dapivirine into the vaginal tissues over the course of four weeks. But there are still several more steps that need to be followed before the ring becomes available to women.

    01 March 2016 | The Conversation
  • Modern HIV Prevention: What’s Next For Women?

    The vaginal ring is one more addition to an already exciting array of antiretroviral-based biomedical options in the prevention toolbox that has ushered in a new era in HIV prevention.

    26 February 2016 | International AIDS Society
  • More investment needed in developing female-controlled HIV prevention options

    Results from two large-scale studies of a vaginal ring that releases the antiretroviral medicine dapivirine to prevent HIV among women have shown protection of around 30% against HIV. The results are encouraging and show the urgent need to expand investment in research and development for female-controlled methods of HIV prevention. Although less effective than hoped for, the results are the first to show that a sustained release mechanism for antiretroviral medicine is feasible, safe and partially effective in preventing HIV infection among women. Follow-up studies are needed to build on these results and there is a need to better understand how to optimize the HIV prevention effect and support adherence.

    24 February 2016 | UNAIDS
  • New tools to fight AIDS

    Kenneth Mayer: Despite our great progress, we require better tools to fight AIDS. That is why there is so much excitement around this year’s annual Conference on Retroviruses and Opportunistic Infections, which will convene in Boston Feb. 22-25. We are going to learn more about two emerging tools to control the HIV/AIDS epidemic: prevention medicines that are easy to use and protect those who are HIV negative from infection, and advances in vaccine research.

    21 February 2016 | Boston Globe
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close